From the Editor

Nov 01, 2012
Pharmaceutical Executive
Spain's leading business school, IESE, organized an expert conference on October 2-3 to address two simple questions. First, how can providers and payers work together to generate more value from existing resources? Second, what must be done to ensure the system continues to create value in the first place?
Oct 01, 2012
Pharmaceutical Executive
Developing a drug is still very much a game of chance: a round puzzle of soft edges, with pieces that rarely fit the hard rectangles of time and money. Solving the puzzle correctly—with a new product as the sum of its parts—depends on making that lengthy progression from basic science to registration as linear as possible.
Sep 01, 2012
Pharmaceutical Executive
Autumn is a good time to present our annual post on how well the industry is doing in harvesting value for shareholders. Our diverse list of 24 companies, drawn from Big Pharma to the established biotechs, presents a similarly mixed picture on returns: smaller firms with a distinct customer base and tight oversight of costs are by and large proving more adept at delivering the strong growth that investors still expect from this business.
Aug 01, 2012
Pharmaceutical Executive
This month's feature by Ben Comer highlights what's behind the new Corporate Integrity Agreement (CIA) imposed on GSK by theHHS Office of Inspector-General to compensate for a long list of marketing and pricing malfeasances
Jul 01, 2012
Pharmaceutical Executive
Pharm Exec's 2012 roster of Emerging Leaders—our sixth to date—is not only a way to recognize a few individuals who've made a difference in their organizations. It also serves as a barometer to track larger changes in the workplace.
Jun 01, 2012
Pharmaceutical Executive
As the old Broadway song goes, June is busting out all over—and true to the season this month's issue stretches the seams with content that ranges from the sublime to the ridiculous.
May 01, 2012
Pharmaceutical Executive
The industry's reputation as a growth industry no one wants to pay for is more secure than ever, writes Pharm Exec Editor William Looney.
Apr 01, 2012
Pharmaceutical Executive
Patents are the chief incentive for drug development. Industry should educate stakeholders about IP protection as a crucial driver of innovation, before it's too late.
Mar 01, 2012
Pharmaceutical Executive
Pharm Exec's latest EAB meeting offered a frank exchange on this magazine's digital future.
Feb 01, 2012
Pharmaceutical Executive
A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
native1_300x100
купить табак аль факер

www.steroid-pharm.com/decabol.html
lorem ipsum